title: Assessing effects of treatment with lisdexamfetamine dimesylate for pediatric ADHD using a parental survey.
abstract: BACKGROUND
  Lisdexamfetamine dimesylate (LDX) is a prodrug stimulant approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6-12 years of age. Parent surveys provide valuable information regarding the impact of ADHD treatments.
  
  
  METHODS
  Parents of children with ADHD beginning treatment with LDX voluntarily completed surveys through an automated telephone system or the Internet before and 6 weeks after LDX treatment initiation. Prescribing physicians received individual reports of the responses for each survey completed by their patients' parents. All patients whose parents completed both baseline and 6 week surveys were included in the analyses. Subgroup analyses were conducted for those previously treated with medications to treat ADHD, including mixed amphetamine salts-extended release.
  
  
  RESULTS
  LDX treatment was associated with a significant decrease in ADHD symptom interference with school activities, family interactions, homework, and social interactions (P<.01; N=11,576). Parents rated satisfaction with LDX as significantly higher than with their child's previous treatment (P<.01). On average, global improvement, tolerability, convenience, and satisfaction with LDX were all highly rated.
  
  
  CONCLUSIONS
  Patients treated with LDX showed significant symptom improvement and parents reported significantly greater satisfaction than with prior treatment.
authors.affiliation: Center for Attention, Mood, and Behavior, St. Petersburg, FL, USA. dlantonuccimd@pol.net
authors.forename: Donna
authors.initials: D
authors.lastname: Antonucci
authors.forename: Craig
authors.initials: C
authors.lastname: Kunins
authors.forename: Michael
authors.initials: M
authors.lastname: Manos
authors.forename: Frank A
authors.initials: FA
authors.lastname: López
authors.forename: Donna L
authors.initials: DL
authors.lastname: Kerney
mesh_terms: D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000453:epidemiology*; D002648:Child; D003913:Dextroamphetamine / Q000627:therapeutic use*; D005260:Female; D006306:Health Surveys; D006801:Humans; D000069478:Lisdexamfetamine Dimesylate; D008297:Male; D017063:Outcome Assessment, Health Care; D010290:Parents / Q000523:psychology*; D010372:Pediatrics; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
chemical_list: D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine